You are here: Industry Insights > BVX-0320

News List

BioVaxys, Wuxi Biologics Enter Bioproduction Agreement contractpharma
March 16, 2021
BioVaxys Technology, a provider of haptenized protein vaccines for antiviral and cancer applications, has entered into a major bioproduction agreement with WuXi Biologics, a global contract development and manufacturing organization (CDMO) and ...
BioVaxys Announces Initiation Of Cancer Vaccine EU Clinical Program, Completion Of BVX-0320 Preclinical Program prnasia
January 26, 2021
BioVaxys Technology Corp. is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021.
BioVaxys Vaccine Platform Stimulates Robust T-cell Response Against Viral Antigens prnasia
December 23, 2020
BioVaxys Technology Corp. announced that further analysis of the data from a preclinical animal study (also known as the "murine model study") of its haptenized viral protein vaccine technology show that BVX-0320, its COVID-19 vaccine candidate based ...